Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives $10.80 Average Price Target from Analysts

Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) have been assigned an average rating of “Moderate Buy” from the six brokerages that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $10.80.

RGLS has been the topic of several recent research reports. StockNews.com upgraded Regulus Therapeutics to a “sell” rating in a research report on Tuesday, September 17th. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Regulus Therapeutics in a report on Monday, November 11th.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Creative Planning purchased a new stake in Regulus Therapeutics in the 3rd quarter valued at approximately $26,000. SG Americas Securities LLC purchased a new stake in shares of Regulus Therapeutics in the third quarter valued at approximately $33,000. Jane Street Group LLC purchased a new stake in shares of Regulus Therapeutics in the third quarter valued at approximately $46,000. Barclays PLC grew its holdings in Regulus Therapeutics by 285.2% during the third quarter. Barclays PLC now owns 84,477 shares of the biopharmaceutical company’s stock worth $132,000 after acquiring an additional 62,549 shares during the period. Finally, Rhumbline Advisers purchased a new position in Regulus Therapeutics in the second quarter worth $136,000. 92.38% of the stock is owned by hedge funds and other institutional investors.

Regulus Therapeutics Price Performance

Shares of Regulus Therapeutics stock opened at $1.59 on Wednesday. The stock has a market capitalization of $104.15 million, a price-to-earnings ratio of -1.49 and a beta of 1.61. The firm’s fifty day simple moving average is $1.53 and its 200-day simple moving average is $1.69. Regulus Therapeutics has a 12 month low of $1.08 and a 12 month high of $3.79.

Regulus Therapeutics (NASDAQ:RGLS) last posted its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.03). Analysts anticipate that Regulus Therapeutics will post -0.88 earnings per share for the current year.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.